Antiviral Drugs - Bosnia and Herzegovina

Bosnia and Herzegovina

The projected revenue in the Antiviral Drugs market in Bosnia and Herzegovina is expected to reach US$6.32m in 2024.
This market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 1.65%, leading to a market volume of US$6.86m by 2029.
In comparison to other countries worldwide, United States is projected to generate the highest revenue in this market, amounting to US$30,640.00m in 2024.
Bosnia and Herzegovina's antiviral drug market is experiencing a surge in demand due to the increasing prevalence of viral infections in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs has been increasing worldwide due to the COVID-19 pandemic. Bosnia and Herzegovina is no exception to this trend.

Customer preferences: Customers in Bosnia and Herzegovina are increasingly seeking antiviral drugs due to the rising cases of COVID-19. The government has also been promoting the use of these drugs to control the spread of the virus.

Trends in the market: The antiviral drugs market in Bosnia and Herzegovina is witnessing growth due to the outbreak of COVID-19. The market is expected to continue to grow in the coming years due to the increasing cases of COVID-19 in the country. The demand for these drugs is expected to remain high until a vaccine is available for the general public.

Local special circumstances: Bosnia and Herzegovina is a small country with a population of around 3.3 million people. The healthcare system in the country is not well developed, and there is a shortage of medical professionals. The government has been taking steps to improve the healthcare system, but progress has been slow.

Underlying macroeconomic factors: The economy of Bosnia and Herzegovina is heavily dependent on exports and remittances. The COVID-19 pandemic has had a negative impact on the economy, and the government has been struggling to mitigate the effects of the pandemic. The healthcare sector has been underfunded for many years, and the pandemic has highlighted the need for increased investment in the sector. The government has been taking steps to improve the healthcare system, but progress has been slow.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.